CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $10,000 | +11.1% | 153 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $9,000 | -25.0% | 153 | -20.7% | 0.00% | 0.0% |
Q1 2022 | $12,000 | +9.1% | 193 | +31.3% | 0.00% | 0.0% |
Q4 2021 | $11,000 | -75.0% | 147 | -63.0% | 0.00% | -80.0% |
Q3 2021 | $44,000 | -22.8% | 397 | +10.9% | 0.01% | -16.7% |
Q2 2021 | $57,000 | +50.0% | 358 | +12.6% | 0.01% | +20.0% |
Q1 2021 | $38,000 | +280.0% | 318 | +367.6% | 0.01% | +400.0% |
Q4 2020 | $10,000 | +66.7% | 68 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $6,000 | +20.0% | 68 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $5,000 | +66.7% | 68 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $3,000 | -25.0% | 68 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $4,000 | – | 68 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |